205 related articles for article (PubMed ID: 24981513)
1. SUMOylation modulates the transcriptional activity of androgen receptor in a target gene and pathway selective manner.
Sutinen P; Malinen M; Heikkinen S; Palvimo JJ
Nucleic Acids Res; 2014 Jul; 42(13):8310-9. PubMed ID: 24981513
[TBL] [Abstract][Full Text] [Related]
2. SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin.
Toropainen S; Malinen M; Kaikkonen S; Rytinki M; Jääskeläinen T; Sahu B; Jänne OA; Palvimo JJ
Nucleic Acids Res; 2015 Jan; 43(2):848-61. PubMed ID: 25552417
[TBL] [Abstract][Full Text] [Related]
3. Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus.
Rytinki M; Kaikkonen S; Sutinen P; Paakinaho V; Rahkama V; Palvimo JJ
Mol Cell Biol; 2012 Oct; 32(20):4195-205. PubMed ID: 22890844
[TBL] [Abstract][Full Text] [Related]
4. Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.
Sutinen P; Rahkama V; Rytinki M; Palvimo JJ
Mol Endocrinol; 2014 Oct; 28(10):1719-28. PubMed ID: 25127374
[TBL] [Abstract][Full Text] [Related]
5. SUMO-specific protease 1 modulates cadmium-augmented transcriptional activity of androgen receptor (AR) by reversing AR SUMOylation.
Wu R; Cui Y; Yuan X; Yuan H; Wang Y; He J; Zhao J; Peng S
Toxicol Lett; 2014 Sep; 229(2):405-13. PubMed ID: 25014244
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
7. The in vivo role of androgen receptor SUMOylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the proline/glycine residues of synergy control motifs.
Mukherjee S; Cruz-Rodríguez O; Bolton E; Iñiguez-Lluhí JA
J Biol Chem; 2012 Sep; 287(37):31195-206. PubMed ID: 22829593
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor.
Guseva NV; Rokhlin OW; Bair TB; Glover RB; Cohen MB
Oncotarget; 2012 Feb; 3(2):183-94. PubMed ID: 22383394
[TBL] [Abstract][Full Text] [Related]
9. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.
Decker KF; Zheng D; He Y; Bowman T; Edwards JR; Jia L
Nucleic Acids Res; 2012 Nov; 40(21):10765-79. PubMed ID: 23019221
[TBL] [Abstract][Full Text] [Related]
10. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel androgen receptor target genes in prostate cancer.
Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor- and PIAS1-regulated gene programs in molecular apocrine breast cancer cells.
Malinen M; Toropainen S; Jääskeläinen T; Sahu B; Jänne OA; Palvimo JJ
Mol Cell Endocrinol; 2015 Oct; 414():91-8. PubMed ID: 26219822
[TBL] [Abstract][Full Text] [Related]
13. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.
Kaikkonen S; Jääskeläinen T; Karvonen U; Rytinki MM; Makkonen H; Gioeli D; Paschal BM; Palvimo JJ
Mol Endocrinol; 2009 Mar; 23(3):292-307. PubMed ID: 19116244
[TBL] [Abstract][Full Text] [Related]
14. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells.
Yuan H; Gong A; Young CY
Carcinogenesis; 2005 Apr; 26(4):793-801. PubMed ID: 15661808
[TBL] [Abstract][Full Text] [Related]
15. Novel lncRNA
Lingadahalli S; Jadhao S; Sung YY; Chen M; Hu L; Chen X; Cheung E
Mol Cancer Res; 2018 Dec; 16(12):1865-1878. PubMed ID: 30115758
[TBL] [Abstract][Full Text] [Related]
16. Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation.
Mukherjee S; Thomas M; Dadgar N; Lieberman AP; Iñiguez-Lluhí JA
J Biol Chem; 2009 Aug; 284(32):21296-306. PubMed ID: 19497852
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells.
Schayek H; Seti H; Greenberg NM; Sun S; Werner H; Plymate SR
Mol Cell Endocrinol; 2010 Jul; 323(2):239-45. PubMed ID: 20417685
[TBL] [Abstract][Full Text] [Related]
18. The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin.
Chen ST; Okada M; Nakato R; Izumi K; Bando M; Shirahige K
J Biol Chem; 2015 Aug; 290(35):21713-23. PubMed ID: 26175158
[TBL] [Abstract][Full Text] [Related]
19. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
Jin HJ; Zhao JC; Wu L; Kim J; Yu J
Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
[TBL] [Abstract][Full Text] [Related]
20. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
